中西医结合治疗肝细胞癌研究进展
Research Progress in the Treatment of Hepatocellular Carcinoma by Combination of Traditional Chinese and Western Medicine
DOI: 10.12677/acm.2024.14112927, PDF,   
作者: 田志鹏:威海市文登区卫生健康局,中医药科,山东 威海;初玉婷:威海市口腔医院,中医理疗科,山东 威海;石 玉*:包头市昆区昆河镇林荫社区卫生服务中心,中医科,内蒙古 包头
关键词: 肝细胞癌手术切除经动脉化疗栓塞免疫疗法中医疗法中西医结合Hepatocellular Carcinoma Surgical Excision Transarterial Chemoembolization Immunotherapy Chinese Medicine Therapy Integration of Traditional Chinese and Western Medicine
摘要: 肝细胞癌是我国常见的消化系统恶性肿瘤,其病因复杂,致病因素广泛,病程进展快,预后差,死亡率高,是严重威胁人类生命健康的疾病之一。目前对于肝细胞癌的治疗,西医方面主要是手术早期切除、肝移植、局部消融治疗、放疗、化疗和免疫治疗等,虽然取得不错的疗效,但仍存在生存率不高,不良反应与复发等问题。综合当前各种治疗方法,不断寻求最优治疗方案显得尤为重要。中医药是一个伟大的宝库,距今已有5000多年的历史,在西医传入之前对华夏人民生命健康作出了巨大的贡献,在西医传入之后,中医药凭借独有的理论和辨证施治的优势依然发挥着不可替代的作用。中医把肝细胞癌病机归结为肝郁脾虚、气滞血瘀、湿热毒聚、肝肾阴虚、气阴两虚,注重辨证论治的个体化治疗,并且始终重视正气的作用,强调整体调节,无论肝细胞癌发展到哪种时期,都可以进行中医药治疗,并且可以配合针刺、艾灸、穴位敷贴等中医特色治疗方法,有效缓解患者临床症状。因此中西医结合治疗肝细胞癌可以优势互补,是降低术后复发率、减少副作用、提高生存率的有效措施。
Abstract: Hepatocellular carcinoma (HCC) is a common malignant tumor of digestive system in China. It has complex etiology, extensive pathogenic factors, rapid course of disease, poor prognosis and high mortality. It is one of the diseases that seriously threaten human life and health. At present, for the treatment of hepatocellular carcinoma, western medicine mainly focuses on early surgical resection, liver transplantation, local ablation therapy, radiotherapy, chemotherapy and immunotherapy, etc. Although good efficacy has been achieved, there are still problems such as low survival rate, adverse reactions and recurrence. Considering all kinds of current treatment methods, it is particularly important to constantly seek the best treatment plan. Traditional Chinese medicine is a great treasure house with a history of more than 5000 years. Before the introduction of Western medicine, traditional Chinese medicine made great contributions to the life and health of the Chinese people. After the introduction of western medicine, traditional Chinese medicine still plays an irreplaceable role with its unique theories and advantages of syndrome differentiation and treatment. TCM ascribed hepatocellular carcinoma to liver stagnation and spleen deficiency, qi stagnation and blood stasis, dampness-heat toxic accumulation, liver and kidney Yin deficiency, qi and Yin deficiency. It pays attention to individual treatment based on syndrome differentiation, and always attaches importance to the role of positive qi, emphasizing overall regulation. No matter what stage hepatocellular carcinoma develops to, TCM treatment can be performed, and it can be combined with acupuncture, moxibustion, acupoint application and other TCM-characteristic treatment methods, effective relieving of patients’ clinical symptoms. Therefore, the combination of traditional Chinese and western medicine in the treatment of hepatocellular carcinoma can complement each other’s advantages, and is an effective measure to reduce the postoperative recurrence rate, reduce side effects and improve the survival rate.
文章引用:田志鹏, 初玉婷, 石玉. 中西医结合治疗肝细胞癌研究进展[J]. 临床医学进展, 2024, 14(11): 644-649. https://doi.org/10.12677/acm.2024.14112927

参考文献

[1] Villanueva, A. (2019) Hepatocellular Carcinoma. New England Journal of Medicine, 380, 1450-1462. [Google Scholar] [CrossRef] [PubMed]
[2] Forner, A., Reig, M. and Bruix, J. (2018) Hepatocellular Carcinoma. The Lancet, 391, 1301-1314. [Google Scholar] [CrossRef] [PubMed]
[3] 张鹭, 江建宁. 原发性肝癌发病机制和治疗的最新进展[J]. 肝脏, 2020, 25(5): 455-458.
[4] 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版) [J]. 中华外科杂志, 2022, 60(4): 273-309.
[5] Pinter, M., Scheiner, B. and Peck-Radosavljevic, M. (2020) Immunotherapy for Advanced Hepatocellular Carcinoma: A Focus on Special Subgroups. Gut, 70, 204-214. [Google Scholar] [CrossRef] [PubMed]
[6] Federico, P., Petrillo, A., Giordano, P., Bosso, D., Fabbrocini, A., Ottaviano, M., et al. (2020) Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. Cancers, 12, Article 3025. [Google Scholar] [CrossRef] [PubMed]
[7] 陆检英, 周海燕, 张高彬, 等. 原发性肝癌中西医结合治疗进展[J]. 中医临床研究, 2019, 11(36): 71-73+85.
[8] 成扬, 倪赛赛, 陈建杰. 陈建杰教授运用中医辨证论治治疗肝癌术后经验探析[J]. 海南医学院学报, 2020, 26(11): 861-863+867.
[9] 任晓琳, 王润珍, 陈剑峰, 等. 李春辉老中医治疗原发性肝癌经验介绍[J]. 新中医, 2020, 52(2): 194-196.
[10] Sugawara, Y. and Hibi, T. (2021) Surgical Treatment of Hepatocellular Carcinoma. BioScience Trends, 15, 138-141. [Google Scholar] [CrossRef] [PubMed]
[11] Chen, Q., Shu, G., Laurence, A.D., et al. (2018) Effect of Huaier Granule on Recurrence after Curative Resection of HCC: A Multi-Centre, Randomized Clinical Trial. Gut, 67, 2006-2016.
[12] 陈红云, 岳小强, 陈喆. 中医治疗方案在肝癌患者术后应用的初步分析[J]. 世界中西医结合杂志, 2012, 7(6): 484-486+525.
[13] 中国中西医结合学会围手术期专业委员会, 广东省中西医结合学会围手术期专业委员会. 中西医结合围手术期胃肠动力管理中国专家共识[J]. 中国中西医结合外科杂志, 2022, 28(1): 6-11.
[14] 牟弘毅, 李雪艳, 陈怡, 等. ERAS理念联合中药灌肠对肝癌术后患者胃肠功能恢复的影响[J]. 中国中医药科技, 2022, 29(3): 435-437.
[15] 何娜娜, 王冬梅, 张新军. 补肾健脾方联合扶正抑瘤方治疗原发性肝癌术后疗效及对血清免疫因子水平的影响[J]. 现代中西医结合杂志, 2017, 26(21): 2309-2311.
[16] 雷华涛. 手术配合中药治疗原发性肝癌Ⅲ期疗效观察[J]. 实用中医药杂志, 2016, 32(1): 50-51.
[17] Chang, Y., Jeong, S.W., et al. (2020) Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 31, Article 8165.
[18] 刘婷莉, 邓艺, 沈轩宇. 癌痛消方联合TACE治疗原发性肝癌临床疗效及对免疫因子的影响[J]. 湖北中医药大学学报, 2021, 23(6): 32-35.
[19] 贾磊, 张跃强, 曾祥学. 参赭培气汤联合TACE治疗原发性肝癌的临床观察[J]. 世界中西医结合杂志, 2022, 17(3): 584-588.
[20] 方良, 林祖庆. 八珍汤合化积丸加减结合肝动脉化疗栓塞术治疗中晚期原发性肝癌临床研究[J]. 新中医, 2020, 52(18): 57-59.
[21] 王静, 贾建伟, 苗静, 等. 肝动脉化疗栓塞联合金龙胶囊治疗血瘀郁结证中晚期肝癌疗效及对机体免疫功能的影响[J]. 山西医药杂志, 2022, 51(4): 367-370.
[22] 陈刚, 吴嫣然, 李婧. 免疫治疗时代对恶性肿瘤中西医结合治疗的思考[J]. 现代中西医结合杂志, 2022, 31(3): 376-380.
[23] 王东, 陈玉晓, 董转丽, 等. 中晚期肝癌免疫治疗现状与前景[J]. 现代肿瘤医学, 2022, 30(11): 2065-2068.
[24] Nakano, S., Eso, Y., Okada, H., Takai, A., Takahashi, K. and Seno, H. (2020) Recent Advances in Immunotherapy for Hepatocellular Carcinoma. Cancers, 12, Article 775. [Google Scholar] [CrossRef] [PubMed]
[25] Qin, S., Ren, Z., Meng, Z., Chen, Z., Chai, X., Xiong, J., et al. (2020) Camrelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma: A Multicentre, Open-Label, Parallel-Group, Randomised, Phase 2 Trial. The Lancet Oncology, 21, 571-580. [Google Scholar] [CrossRef] [PubMed]
[26] Vogel, A., Bathon, M. and Saborowski, A. (2021) Advances in Systemic Therapy for the First-Line Treatment of Unresectable HCC. Expert Review of Anticancer Therapy, 21, 621-628. [Google Scholar] [CrossRef] [PubMed]
[27] 丁晓毅, 王征, 石洁, 等. 中国肝癌多学科综合治疗专家共识[J]. 临床肝胆病杂志, 2021, 37(2): 278-285.
[28] 程石, 张洪义. 中晚期肝细胞癌的免疫靶向治疗现状[J]. 中国临床医生杂志, 2020, 50(5): 523-526.
[29] 杨丽惠, 胡凯文, 王婧筱. 基于肝癌免疫微环境探讨活血化痰解毒法在肝癌中的作用机制[J]. 中国实验方剂学杂志, 2022, 28(14): 172-178.
[30] 张想, 夏黎明. 疏肝理脾方联合卡瑞利珠单抗治疗晚期原发性肝癌临床观察[J]. 山西中医, 2022, 38(2): 37-39.
[31] 邓哲. 薯蓣丸抑制HIF-1α改善肝癌微环境缺氧与免疫逃逸的机制研究[D]: [硕士学位论文]. 长沙: 湖南中医药大学, 2020.
[32] 唐亚乐, 韩涛. 黄芪四君子汤对气血亏虚型中晚期原发性肝癌免疫功能的影响[J]. 实用中医内科杂志, 2021, 35(9): 20-22.
[33] 龚纯, 曹献, 谢小玲, 等. 中西医治疗原发性肝癌的研究进展[J]. 大众科技, 2021, 23(5): 87-90.
[34] 钊梦媛, 张国梁. 中医药治疗原发性肝癌的切入点与难点[J]. 临床肝胆病杂志, 2021, 37(9): 2016-2024.